Tag: B7-H4

In a statement Pfizer confirmed that it has discontinued the development of felmetatug vedotin (also known as PF-08046048 or SGN-B7H4V; see Drugmap).

The U.S. Food and Drug Administration (FDA) recently granted an additional Fast Track designation to emiltatug ledadotin (XMT-1660; see ADC Drugmap), an antibody-drug conjugate (ADC) targeting B7-H4 (VTCN1), an immune-suppressive plasma membrane protein that is overexpressed in multiple tumor types, including in breast, ovarian, and endometrial cancers, with relatively little or no expression in normal, or healthy, tissues.

GSK and Duality Biologics have entered into an exclusive option agreement for developing and commercializing DB-1324, a potentially best-in-class antibody-drug conjugate (ADC) candidate.